If you took Elmiron (pentosan polysulfate sodium) for interstitial cystitis and later developed vision problems, you may be entitled to significant compensation. Thousands of patients have filed Elmiron lawsuits alleging that the drug's manufacturer failed to warn about the risk of permanent retinal damage. This guide explains the Elmiron litigation, who qualifies, what compensation may be available, and how to file a claim in 2026.
What Is Elmiron?
Elmiron (pentosan polysulfate sodium, or PPS) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) in 1996 as the only oral treatment for interstitial cystitis (IC), also known as painful bladder syndrome. Interstitial cystitis is a chronic condition that causes bladder pressure, bladder pain, and pelvic pain, and it affects millions of Americans — predominantly women.
Elmiron works by forming a protective coating on the bladder wall, shielding it from irritating substances in urine. For many patients, it was the only long-term oral option available, and doctors prescribed it for years — sometimes decades — of continuous use. Because interstitial cystitis is a chronic condition with no cure, many patients stayed on Elmiron for a very long time, accumulating substantial lifetime exposure to the drug.
Elmiron was manufactured and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. In the United States, Elmiron was sold as a brand-name drug for most of its history, though generic versions of pentosan polysulfate sodium later became available.
The Elmiron Lawsuits: What Happened?
The Elmiron lawsuits center on a serious allegation: that long-term use of Elmiron can cause a distinctive form of retinal damage called pigmentary maculopathy, and that the manufacturer failed to warn patients and doctors about this risk for decades.
The link between Elmiron and eye damage first gained widespread attention in 2018, when researchers at the Emory Eye Center published findings describing a new pattern of retinal damage in patients with long-term Elmiron exposure. The researchers identified six patients who had taken Elmiron for an average of about 15 years and who all showed a distinctive pattern of pigmentary changes in the macula — the central part of the retina responsible for sharp, detailed vision. The pattern did not match any previously known retinal disease, which suggested that Elmiron itself was the cause.
Subsequent studies confirmed and expanded these findings. Researchers found a dose-dependent relationship: the more Elmiron a patient had taken over their lifetime, and the longer they had used it, the more severe the retinal damage tended to be. A 2019 study found that roughly one in four patients with significant Elmiron exposure showed signs of retinal toxicity. Later research confirmed that the damage could progress even after patients stopped taking the drug.
Plaintiffs allege that Janssen knew — or should have known — about the risk of retinal damage far earlier than it warned the public. Internal documents and the timeline of scientific knowledge are central issues in the litigation. The FDA did not require a warning about retinal damage on the Elmiron label until June 2020, when the label was finally updated to include warnings about pigmentary maculopathy. By then, Elmiron had been on the U.S. market for nearly 25 years, and countless patients had accumulated years of exposure without any warning about eye damage.
Thousands of lawsuits have been filed across the United States. The federal cases were consolidated into a multidistrict litigation (MDL) in the District of New Jersey — MDL No. 2973, In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation — before Judge Brian R. Martinotti. Additional cases have been filed in state courts, including a coordinated proceeding in New Jersey state court and cases in Pennsylvania. The litigation has proceeded through discovery, expert testimony, and bellwether trial preparation, with settlements resolving many claims.
Elmiron Eye Damage: What Is Pigmentary Maculopathy?
Pigmentary maculopathy associated with Elmiron is a form of retinal toxicity that damages the macula, the part of the retina responsible for central vision. Symptoms may include:
- Difficulty reading or seeing fine detail, even with glasses.
- Blurred or distorted central vision, including wavy or missing spots.
- Difficulty adapting to dim light or seeing in low-light conditions.
- Trouble distinguishing colors or perceiving contrast.
- Blind spots (scotomas) in the central visual field.
- Eye strain, halos, or glare that worsen over time.
One of the most troubling aspects of Elmiron-related maculopathy is that the damage is generally irreversible. There is no treatment that can restore retinal tissue once it has been damaged. In some cases, the condition continues to progress even after the patient stops taking Elmiron. This means that patients who took Elmiron for years may face a lifetime of impaired vision.
Diagnosis typically requires a comprehensive retinal examination, including fundus photography, optical coherence tomography (OCT), and fundus autofluorescence imaging. Because pigmentary maculopathy can resemble other retinal conditions — such as age-related macular degeneration or pattern dystrophy — it is important to see a retina specialist who is familiar with Elmiron toxicity, and to tell every eye doctor about your history of Elmiron use.
Who Qualifies for an Elmiron Lawsuit?
You may qualify to file an Elmiron lawsuit if you meet the following general criteria:
- You took Elmiron (pentosan polysulfate sodium) — brand-name Elmiron or a generic version — for interstitial cystitis or another condition.
- You used the drug for a substantial period. Most claims involve at least six months to one year of use, and many involve several years. Longer use and higher cumulative doses are associated with stronger claims, but even shorter-term users with diagnosed retinal damage should consult a lawyer.
- You were diagnosed with pigmentary maculopathy, retinal toxicity, or another qualifying vision condition after using Elmiron. A diagnosis from an ophthalmologist or retina specialist is essential.
- Your claim is within the applicable statute of limitations. Deadlines vary by state and depend on when you discovered (or should have discovered) the connection between Elmiron and your eye damage. Because these deadlines are strict, it is important to act promptly.
Even if you are unsure whether your vision problems are related to Elmiron, an experienced Elmiron lawyer can review your medical records and help determine whether you have a viable claim. Many law firms offer free case evaluations, and you pay nothing unless you recover compensation.
Family members may also have claims in certain circumstances. If a loved one passed away after suffering Elmiron-related injuries, surviving family members may be able to pursue a wrongful death claim under state law.
Compensation in Elmiron Lawsuits
Compensation in an Elmiron lawsuit may cover several categories of damages:
Economic Damages
- Medical expenses: Past and future costs of eye examinations, retinal imaging, specialist visits, corrective lenses, low-vision aids, and any ongoing eye care.
- Lost wages: Income lost because vision problems interfered with your ability to work.
- Loss of earning capacity: Reduced ability to earn a living in the future due to permanent vision impairment.
- Out-of-pocket costs: Travel to specialists, assistive devices, home modifications, and other expenses caused by vision loss.
Non-Economic Damages
- Pain and suffering: Physical discomfort and emotional distress caused by vision loss.
- Loss of enjoyment of life: Inability to read, drive, recognize faces, or enjoy hobbies and activities that required clear vision.
- Mental anguish: Anxiety, depression, and emotional harm resulting from permanent vision damage.
- Loss of independence: Needing help with daily tasks that you previously performed on your own.
Punitive Damages
In some cases, plaintiffs may seek punitive damages, which are intended to punish the manufacturer for particularly egregious conduct — such as failing to warn about a known risk — and to deter similar behavior in the future. Punitive damages are not available in every state or every case, and they are typically awarded only when the evidence shows willful or reckless misconduct.
Elmiron Settlement Values in 2026
It is impossible to predict the exact value of any individual Elmiron claim, because settlement values depend on the specific facts of each case. However, several factors generally influence how much a claim may be worth:
- Severity of vision damage: Mild retinal changes with minimal symptoms typically result in lower compensation than severe, permanent vision loss.
- Duration and cumulative dose of Elmiron use: Longer use and higher total doses tend to strengthen causation and increase claim value.
- Impact on daily life and work: Claimants who lost jobs, careers, or independence due to vision damage generally recover more.
- Age: Younger claimants with decades of impaired vision ahead of them may recover more for future damages.
- Medical costs: Higher past and anticipated future medical expenses increase economic damages.
- Strength of the evidence: Clear documentation linking Elmiron use to retinal damage — including pharmacy records, prescription history, and retinal imaging — strengthens a claim.
Published reports on Elmiron settlements have varied widely. Some claims involving mild or moderate damage have settled for tens of thousands of dollars, while claims involving severe, permanent vision loss have reportedly settled for significantly more. Individual results depend on the facts, the jurisdiction, and the strength of the evidence. An experienced Elmiron attorney can evaluate your case and provide a realistic assessment of its potential value.
It is important to be wary of any lawyer or website that guarantees a specific settlement amount. No attorney can promise a particular outcome, and any firm that does so should be viewed with skepticism.
Individual Lawsuit vs. Class Action vs. MDL
Elmiron claims are generally handled as individual lawsuits consolidated in an MDL — not as a class action. Understanding the difference matters:
- Individual lawsuit: You file your own case, and any settlement or verdict is based on your specific injuries and damages.
- Class action: A single case represents a large group of people with similar claims, and all members share in one settlement. Class actions are rare in pharmaceutical injury cases because injuries vary so much from person to person.
- Multidistrict litigation (MDL): Individual cases are consolidated before one judge for pretrial proceedings (discovery, expert testimony, bellwether trials), but each case remains separate. If a case does not settle, it is sent back to its original court for trial. The Elmiron litigation has proceeded as an MDL, which allows for efficient handling of common issues while preserving each plaintiff's individual claim.
Most Elmiron plaintiffs file individual lawsuits that are transferred into the MDL. Your lawyer will handle the procedural details; what matters for you is preserving your medical records and acting before the statute of limitations expires.
How to File an Elmiron Lawsuit: 7 Steps
- See a retina specialist. If you took Elmiron and have any vision symptoms, get a comprehensive retinal examination. Ask for OCT and fundus autofluorescence imaging, and make sure the doctor documents your Elmiron history in your medical records.
- Gather your records. Collect pharmacy records showing Elmiron prescriptions, dates, and dosages; medical records documenting interstitial cystitis and eye examinations; and any records of vision problems, treatments, and costs.
- Do not delay. Statutes of limitations vary by state — typically one to three years from the date you discovered (or should have discovered) the connection between Elmiron and your eye damage, though some states allow longer. Missing the deadline can bar your claim entirely.
- Choose an experienced Elmiron lawyer. Look for a firm with a track record in pharmaceutical mass tort litigation, experience with the Elmiron MDL, and the resources to hire medical experts. Most firms offer free consultations.
- Sign a contingency fee agreement. Most Elmiron lawyers work on contingency — typically 33% to 40% of any recovery — meaning you pay nothing upfront and owe nothing unless you win.
- Let your lawyer build your case. Your legal team will gather evidence, obtain expert opinions from ophthalmologists and pharmacologists, and handle filings, discovery, and negotiations.
- Decide whether to settle or go to trial. Most pharmaceutical cases settle. Your lawyer will advise you on any settlement offer, but the final decision is yours. If a fair settlement cannot be reached, your case may proceed to trial.
Statute of Limitations: Why Timing Matters
Every state sets a deadline — the statute of limitations — for filing a personal injury lawsuit. In Elmiron cases, the clock generally starts when you knew (or reasonably should have known) that Elmiron caused your eye damage. This is known as the discovery rule, and it is critical in Elmiron cases because many patients did not learn about the connection until years after they stopped taking the drug.
Deadlines vary significantly: some states allow only one year, while others allow up to six. Certain states also have statutes of repose that set an absolute outer limit regardless of when you discovered the injury. Because these rules are complex and state-specific, the safest course is to contact an Elmiron lawyer as soon as possible after a diagnosis of pigmentary maculopathy. Waiting to see whether your vision worsens can cost you the right to recover anything at all.
How to Choose the Right Elmiron Lawyer
Choosing the right attorney can make a significant difference in the outcome of your case. Consider the following:
- Experience with pharmaceutical mass torts. Elmiron cases involve complex science, FDA regulatory history, and MDL procedure. Choose a firm that has handled drug injury cases — ideally Elmiron cases specifically.
- Resources. Mass tort litigation requires substantial resources for expert witnesses, medical record review, and discovery. Make sure the firm can fund your case through trial if necessary.
- Communication. Your lawyer should explain the process clearly, return your calls, and keep you updated on the status of your case.
- Fee structure. Confirm that the firm works on contingency, and understand exactly what percentage they will take and whether case costs are deducted before or after the fee is calculated.
- No upfront fees. Reputable Elmiron lawyers do not charge upfront fees for case evaluations or filings.
Be cautious of firms that pressure you to sign immediately, guarantee a specific result, or refuse to explain their fee structure in writing.
Common Mistakes to Avoid
- Waiting too long to act. Statutes of limitations are strict. Delay can destroy an otherwise valid claim.
- Stopping Elmiron without talking to your doctor. Do not stop any prescribed medication without medical advice. If you are still taking Elmiron, discuss the risks and alternatives with your prescribing physician and an eye specialist.
- Skipping the retina specialist. A general eye exam may not detect pigmentary maculopathy. You need specialized retinal imaging and a doctor familiar with Elmiron toxicity.
- Failing to preserve records. Pharmacy records, prescription bottles, and medical files are essential evidence. Save everything.
- Posting about your case on social media. Defense lawyers may monitor social media. Avoid discussing your case, symptoms, or legal strategy online.
- Accepting a quick settlement without legal advice. Early settlement offers may be far below the true value of your claim. Consult a lawyer before accepting anything.
- Signing documents from the manufacturer or insurer. Do not sign releases or settlement agreements without having an attorney review them.
Frequently Asked Questions
Can I still file if I stopped taking Elmiron years ago? Yes. Many plaintiffs stopped taking Elmiron years before filing. What matters is whether you can show Elmiron use and a diagnosis of retinal damage, and whether you are within the statute of limitations under your state's discovery rule.
What if I took generic pentosan polysulfate sodium instead of brand-name Elmiron? Generic versions contain the same active ingredient, and claims involving generics have been pursued. Discuss your specific medication history with your lawyer.
Will I have to go to court? Most Elmiron cases settle without a trial. However, your lawyer should be prepared to take your case to trial if a fair settlement is not offered.
How long does an Elmiron lawsuit take? Mass tort cases can take months to years depending on the MDL schedule, settlement negotiations, and whether bellwether trials occur. Your lawyer can give you a more specific timeline based on the current status of the litigation.
What if my eye doctor said my condition is age-related macular degeneration? Elmiron-related maculopathy can be misdiagnosed as age-related macular degeneration or pattern dystrophy. If you took Elmiron, consider getting a second opinion from a retina specialist familiar with Elmiron toxicity.
Does filing a lawsuit affect my medical care? No. Filing a lawsuit does not affect your right to medical treatment. Continue seeing your doctors and following their recommendations.
The Bottom Line
Elmiron lawsuits allege that long-term use of a drug prescribed for interstitial cystitis caused permanent retinal damage — and that patients were never warned. If you took Elmiron and were diagnosed with pigmentary maculopathy or another vision condition, you may be entitled to compensation for medical expenses, lost income, pain and suffering, and more. The science linking Elmiron to retinal toxicity is well established, thousands of claims have been filed, and settlements have resolved many cases.
Time limits apply, and the evidence you preserve today — pharmacy records, retinal imaging, and medical files — can make the difference in your claim. Contact an experienced Elmiron lawyer for a free case evaluation, and do not stop taking any prescribed medication without talking to your doctor first.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Elmiron litigation is ongoing and outcomes vary by case. Consult a licensed attorney in your state about your specific situation.
